MetaCap

Nephros (NEPH) vs TELA Bio (TELA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TELA Bio (TELA) has outperformed Nephros (NEPH) over the past year, losing 41.2% versus a loss of 46.4%. Over five years, NEPH leads with a -63.6% price change compared with -94.4% for TELA. TELA Bio is the larger company by market cap ($31.1 million vs $28.4 million), about 1.1 times the size, while Nephros is growing revenue faster (+32.7% vs +15.8%).

Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -48.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NEPH-46.41%TELA-41.15%
+24%-16%-56%
Nov 21, 20251 yearNov 20, 2026
NEPH-64.82%TELA-94.54%
+6%-47%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NEPH versus TELA key metrics
MetricNEPHTELA
Share price$2.61$0.6885
Market cap$28.37M$31.11M
1-day change-8.10%-5.27%
YTD return-46.52%-41.65%
1-year return-46.41%-41.15%
5-year return-63.60%-94.37%
P/E ratio (TTM)15.35—
Forward P/E11.86—
EPS (TTM)$0.17$-0.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$18.79M$80.28M
Revenue growth (YoY)+32.67%+15.84%
Net income (latest FY)$1.19M$-38.83M
Gross margin61.87%67.69%
Operating margin6.10%-42.05%
Net margin6.35%-48.37%
52-week high$6.42$1.50
52-week low$2.61$0.501
Distance from 52-week high-59.35%-54.10%
Analyst consensusnonestrong_buy
Avg. price target upside+139.46%+202.11%
Average volume48.33K217.44K
Shares outstanding10.87M45.19M
Employees36218
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -48.4 cents for TELA Bio.
  • Nephros grew revenue faster in its latest fiscal year (+32.67% vs +15.84%).

About Nephros

NEPH stock →

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.

Health Care · Medical/Dental Instruments · 36 employees

About TELA Bio

TELA stock →

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Health Care · Medical/Dental Instruments · 218 employees

NEPH vs TELA FAQ

Which is bigger, Nephros or TELA Bio?

TELA Bio (TELA) is larger, with a market capitalization of $31.11M compared with $28.37M for Nephros (NEPH).

Which stock has performed better over the past year, NEPH or TELA?

TELA returned -41.15% over the past 12 months, compared with -46.41% for NEPH (price return, excluding dividends). Past performance does not predict future results.

Are Nephros and TELA Bio in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons